David Robertson, MD

December 23, 2024

Panelists discuss how screening for Type 1 diabetes should focus on identifying high-risk individuals through family history, genetic markers, and autoantibody testing, while emphasizing the importance of early detection to prevent diabetic ketoacidosis at diagnosis.

December 21, 2024

Panelists discuss how delayed intervention in stage II type 1 diabetes can accelerate β cell destruction, leading to more severe clinical onset, increased risk of serious complications like diabetic ketoacidosis, and poorer long-term outcomes.

December 21, 2024

Panelists discuss how type 1 diabetes progresses through distinct stages, beginning with asymptomatic autoantibody presence, followed by dysglycemia, and ultimately manifesting with classic symptoms like excessive thirst, frequent urination, and unexplained weight loss.

December 21, 2024

Panelists discuss early testing with autoantibody screening for type 1 diabetes in at-risk individuals, particularly those with family history or genetic predisposition, to avoid DKA at diagnosis and allow time for patient and family preparation.

December 21, 2024

Panelists discuss the burden of living with type 1 diabetes, including high levels of stress and anxiety and talk about how they help patients manage the daily requirements.

December 19, 2024

Panelists discuss how Type 1 diabetes imposes significant physical, emotional, and financial burdens on patients through the lifelong need for insulin therapy, blood glucose monitoring, lifestyle modifications, and management of potential complications.